These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 17938793)

  • 1. Immunogenicity of novel recombinant human activated factor VII analogues on factor VII neonatally-tolerized rats.
    Sommer C; Norbert Jørgensen P; Salanti Z; Clausen JT; Jensen LB
    Thromb Haemost; 2007 Oct; 98(4):721-5. PubMed ID: 17938793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of potential antigenicity of active-site-inhibited recombinant human FVIIa (FFR-rFVIIa) in an immune-tolerant rat model.
    Nicolaisen EM; Kristensen H; Kristensen A; Hedner U
    Thromb Haemost; 2002 May; 87(5):836-9. PubMed ID: 12038786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy.
    Petrini P; Klementz G
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S143-6. PubMed ID: 9819046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accumulation of the recombinant factor VIIa in rat bone: importance of the Gla-domain and relevance to factor IX, another vitamin K-dependent clotting factor.
    Thomsen MK; Wildgoose P; Nilsson P; Hedner U
    Pharmacol Toxicol; 1993 Sep; 73(3):127-32. PubMed ID: 7903449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful control of central nervous system bleeding in two newborns with severe factor VII deficiency using rFVIIa administered via Port-a-Cath.
    Karimi M
    Semin Hematol; 2008 Apr; 45(2 Suppl 1):S74. PubMed ID: 18544432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity.
    Mahlangu JN; Weldingh KN; Lentz SR; Kaicker S; Karim FA; Matsushita T; Recht M; Tomczak W; Windyga J; Ehrenforth S; Knobe K;
    J Thromb Haemost; 2015 Nov; 13(11):1989-98. PubMed ID: 26362483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
    Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
    Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development.
    Jurlander B; Thim L; Klausen NK; Persson E; Kjalke M; Rexen P; Jørgensen TB; Østergaard PB; Erhardtsen E; Bjørn SE
    Semin Thromb Hemost; 2001 Aug; 27(4):373-84. PubMed ID: 11547359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall experience with NovoSeven.
    Négrier C; Lienhart A
    Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S19-24. PubMed ID: 10850559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery.
    Bowman LJ; Uber WE; Stroud MR; Christiansen LR; Lazarchick J; Crumbley AJ; Kratz JM; Toole JM; Crawford FA; Ikonomidis JS
    Ann Thorac Surg; 2008 May; 85(5):1669-76; discussion 1676-7. PubMed ID: 18442563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant activated factor VII (rFVIIa, NovoSeven).
    Agarwal MB; Patnaik M
    J Assoc Physicians India; 2005 Aug; 53():717-20. PubMed ID: 16398083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.
    Morfini M; Auerswald G; Kobelt RA; Rivolta GF; Rodriguez-Martorell J; Scaraggi FA; Altisent C; Blatny J; Borel-Derlon A; Rossi V
    Haemophilia; 2007 Sep; 13(5):502-7. PubMed ID: 17880436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.
    Mayo A; Misgav M; Kluger Y; Geenberg R; Pauzner D; Klausner J; Ben-Tal O
    Vox Sang; 2004 Jul; 87(1):34-40. PubMed ID: 15260820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization of recombinant activated factor VII in southern Ontario in 85 patients with and without haemophilia.
    Webert KE; Arnold DM; Carruthers J; Molnar L; Almonte T; Decker K; Seroski W; Reed J; Chan AK; Pai M; Walker IR
    Haemophilia; 2007 Sep; 13(5):518-26. PubMed ID: 17880438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial.
    Pruthi RK; Mathew P; Valentino LA; Sumner MJ; Seremetis S; Hoots WK;
    Thromb Haemost; 2007 Oct; 98(4):726-32. PubMed ID: 17938794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
    Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV
    Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of recombinant activated factor VII in unselected patients with uncontrolled haemorrhage: a single centre experience.
    Payne EM; Brett SJ; Laffan MA
    Blood Coagul Fibrinolysis; 2006 Jul; 17(5):397-402. PubMed ID: 16788316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant factor VIIa in paediatric bleeding disorders--a 2006 review.
    Mathew P; Young G
    Haemophilia; 2006 Sep; 12(5):457-72. PubMed ID: 16919075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant activated factor VII efficacy and safety in a model of bleeding and thrombosis in hypothermic rabbits: a blind study.
    Godier A; Mazoyer E; Cymbalista F; Cupa M; Samama CM
    J Thromb Haemost; 2007 Feb; 5(2):244-9. PubMed ID: 17129221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency.
    Ingerslev J; Holm M; Christiansen K; Knudsen L; Négrier C
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S129-34. PubMed ID: 9819044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.